Vanguard Capital Management
DNTH icon

Vanguard Capital Management’s Dianthus Therapeutics DNTH Stock Holding History

Vanguard Capital Management’s Portfolio DNTH Stock Details DNTH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$214M Buy
2,428,073
+268,505
+12% +$27.9M ﹤0.01% 1060
2026
Q2 		$211M Buy
2,159,568
+128,319
+6% +$11.2M ﹤0.01% 1101
2026
Q1 		$170M Buy
+2,031,249
New +$118M ﹤0.01% 1154

Other funds holding DNTH

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return
BlackRock
BlackRock New York $6.79T AUM 37.06% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.21T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $474B AUM 32.39% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $103B AUM 40.17% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $30.6B AUM 42.55% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $106B AUM 32.76% 1-Year Est. Return

Vanguard Capital Management's DNTH Position: Q3 2026 in Review

Vanguard Capital Management increased its Dianthus Therapeutics (DNTH) stake by 12% in Q3 2026, buying an estimated $27.9M and bringing the position to 2,428,073 shares worth $214M. The position accounts for ﹤0.01% of the portfolio, ranked #1060.

Vanguard Capital Management first reported a position in DNTH in Q1 2026 and has held it in 3 quarters since. 188 funds tracked by Wall St. Rank hold DNTH as of Q3 2026.

  • Vanguard Capital Management held 2,428,073 shares of Dianthus Therapeutics worth $214M as of Q3 2026.
  • Vanguard Capital Management bought 268,505 Dianthus Therapeutics shares in Q3 2026, an estimated $27.9M.
  • Dianthus Therapeutics made up ﹤0.01% of Vanguard Capital Management's portfolio in Q3 2026, its #1060 holding.
  • Vanguard Capital Management first reported a position in Dianthus Therapeutics in Q1 2026 and has held it in 3 quarters since.
  • 188 funds tracked by Wall St. Rank held Dianthus Therapeutics as of Q3 2026.

Based on Vanguard Capital Management's 13F filing for Q3 2026, filed 13 Nov 2026.